Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in ...
The FDA has granted Orphan Drug Designation to tovecimig (CTX-009) for the treatment of patients with biliary tract cancer ...
Findings show microplastics in bile may trigger cellular senescence, suggesting a link to gallstone disease and highlighting ...
Comparison outcome of transarterial chemoembolization combined with immune checkpoint inhibitors plus bevacizumab or lenvatinib as first-line therapy for advanced hepatocellular carcinoma. Comparative ...
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of ...
Findings showed that pembrolizumab plus chemotherapy reduced the risk of death by 17% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) ...
Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...
Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
Intrahepatic and perihilar cholangiocarcinoma, in particular, grew faster in young patients than in older patients. The report affirms research from other Western countries suggesting such a trend.
The US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for locally advanced unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results